Search
EyePoint Pharmaceuticals Inc
EYPTAdd to Watchlist
4.250USD
+0.020+0.47%
Close 09-14 16:00（ET）
361.17MMarket Cap
LossP/E TTM
EyePoint Pharmaceuticals Inc (EYPT) Revenue Performance
Updated: Dec 31, 2025Last year, EyePoint Pharmaceuticals Inc generated 1.60M USD for its biggest-performing segment, YUTIQ. The United States made the largest contribution, accounting for 29.98M USD last year.
By Business
Revenue
Proportion
Annual
Annual
Quarterly
YUTIQ
DEXYCU
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
YUTIQ
1.60M(100.00%)
3.10M(100.00%)
14.23M(100.00%)
28.33M(70.99%)
16.96M(48.03%)
13.88M(66.62%)
12.05M(71.60%)
DEXYCU
--(--)
--(--)
--(--)
11.58M(29.01%)
18.35M(51.97%)
6.95M(33.38%)
4.78M(28.40%)
By Region
Revenue
Proportion
Annual
Annual
Quarterly
United States
China
United Kingdom
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
United States
29.98M(95.56%)
42.05M(97.17%)
45.27M(98.37%)
40.48M(97.77%)
35.99M(97.43%)
22.62M(65.70%)
19.14M(94.00%)
1.11M(37.84%)
China
1.29M(4.12%)
1.12M(2.60%)
648.00K(1.41%)
823.00K(1.99%)
851.00K(2.30%)
11.71M(34.01%)
1.12M(5.50%)
1.72M(58.74%)
United Kingdom
100.00K(0.32%)
100.00K(0.23%)
100.00K(0.22%)
100.00K(0.24%)
100.00K(0.27%)
100.00K(0.29%)
100.00K(0.49%)
100.00K(3.42%)